• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Visceral Leishmaniasis in 2 Patients Treated With Lenalidomide and Dexamethasone: A Possible Correlation With Blunted Immune Response.

作者信息

Hadjiaggelidou Christina, Vadikolia Chrysanthi, Verrou Evgenia, Yiannaki Efthalia, Triantafyllou Theodora, Palaska Vasiliki, Keramidioti Konstantina, Tsirou Kyriaki, Papanikolaou Asimina, Markala Dimitra, Konstantinidou Pavlina, Katodritou Eirini

机构信息

Hematology Department, Theagenion Cancer Hospital, Thessaloniki, Greece.

Hematology Department, 424 Military Hospital, Thessaloniki, Greece.

出版信息

Hemasphere. 2020 Dec 9;5(1):e506. doi: 10.1097/HS9.0000000000000506. eCollection 2021 Jan.

DOI:10.1097/HS9.0000000000000506
PMID:33324952
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7732337/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f37/7732337/56ebbae88c9c/hs9-5-e506-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f37/7732337/56ebbae88c9c/hs9-5-e506-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f37/7732337/56ebbae88c9c/hs9-5-e506-g001.jpg

相似文献

1
Visceral Leishmaniasis in 2 Patients Treated With Lenalidomide and Dexamethasone: A Possible Correlation With Blunted Immune Response.2例接受来那度胺和地塞米松治疗的内脏利什曼病患者：与免疫反应减弱的可能相关性
Hemasphere. 2020 Dec 9;5(1):e506. doi: 10.1097/HS9.0000000000000506. eCollection 2021 Jan.
2
Leishmania donovani: impairment of the cellular immune response against recombinant ornithine decarboxylase protein as a possible evasion strategy of Leishmania in visceral leishmaniasis.杜氏利什曼原虫：针对重组鸟氨酸脱羧酶蛋白的细胞免疫反应受损，这可能是利什曼原虫在内脏利什曼病中的一种逃避策略。
Int J Parasitol. 2015 Jan;45(1):33-42. doi: 10.1016/j.ijpara.2014.08.013. Epub 2014 Oct 15.
3
Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas.来那度胺联合小剂量地塞米松和利妥昔单抗治疗利妥昔单抗耐药的惰性和套细胞淋巴瘤可获得持久缓解。
Cancer. 2014 Jan 15;120(2):222-8. doi: 10.1002/cncr.28405. Epub 2013 Oct 7.
4
Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies.硼替佐米或来那度胺一线治疗原发性系统性轻链（AL）淀粉样变患者的长期结局及风险适应策略的重要性。
Am J Hematol. 2015 Apr;90(4):E60-5. doi: 10.1002/ajh.23936. Epub 2015 Mar 9.
5
The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy.来那度胺对 NK 细胞功能的免疫刺激作用会被同时进行的地塞米松治疗显著抑制。
Blood. 2011 Feb 3;117(5):1605-13. doi: 10.1182/blood-2010-04-278432. Epub 2010 Oct 26.
6
Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study.英地昔单抗瑞妥昔单抗联合来那度胺或泊马度胺治疗复发/难治性多发性骨髓瘤的多中心 1/2a 期研究。
Lancet Haematol. 2021 Nov;8(11):e794-e807. doi: 10.1016/S2352-3026(21)00208-8. Epub 2021 Sep 13.
7
Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma.来那度胺：治疗复发性或难治性多发性骨髓瘤的研究进展。
Drugs. 2011 Mar 26;71(5):625-49. doi: 10.2165/11206420-000000000-00000.
8
Spotlight on lenalidomide in relapsed or refractory multiple myeloma.聚焦来那度胺治疗复发/难治性多发性骨髓瘤。
BioDrugs. 2011 Oct 1;25(5):333-7. doi: 10.2165/11207120-000000000-00000.
9
Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure.来那度胺联合地塞米松治疗复发或难治性多发性骨髓瘤患者，无论之前是否使用过沙利度胺，均比单独使用地塞米松更有效。
Blood. 2008 Dec 1;112(12):4445-51. doi: 10.1182/blood-2008-02-141614. Epub 2008 Sep 17.
10
Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice.在常规临床实践中，来那度胺和地塞米松（Rd）与伊沙佐米、来那度胺和地塞米松（IRD）相比，对复发和难治性多发性骨髓瘤患者的生存获益。
BMC Cancer. 2021 Jan 15;21(1):73. doi: 10.1186/s12885-020-07732-1.

引用本文的文献

1
Visceral leishmaniasis in heavily pretreated multiple myeloma patients a case series of 17 patients from the Mediterranean Coast of Spain.重度预处理多发性骨髓瘤患者的内脏利什曼病：来自西班牙地中海沿岸的17例病例系列
Ann Med. 2025 Dec;57(1):2514075. doi: 10.1080/07853890.2025.2514075. Epub 2025 Jun 5.
2
Total serum -glycans mark visceral leishmaniasis in human infections with .总血清聚糖可标记人类感染……时的内脏利什曼病。 （原文中“with.”部分内容不完整）
iScience. 2023 Jun 5;26(7):107021. doi: 10.1016/j.isci.2023.107021. eCollection 2023 Jul 21.

本文引用的文献

1
Functional aspects of T cell diversity in visceral leishmaniasis.内脏利什曼病中 T 细胞多样性的功能方面。
Biomed Pharmacother. 2019 Sep;117:109098. doi: 10.1016/j.biopha.2019.109098. Epub 2019 Jun 10.
2
Evaluation of regulatory T cells (Tregs) alterations in patients with multiple myeloma treated with bortezomib or lenalidomide plus dexamethasone: correlations with treatment outcome.硼替佐米或来那度胺联合地塞米松治疗多发性骨髓瘤患者调节性 T 细胞（Tregs）改变的评估：与治疗结果的相关性。
Ann Hematol. 2019 Jun;98(6):1457-1466. doi: 10.1007/s00277-019-03657-3. Epub 2019 Mar 20.
3
Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or anti-SLAMF7) containing triplets: one shared story of two exceptional cases.
在含单克隆抗体（抗CD38或抗信号淋巴细胞激活分子家族成员7）的三联疗法时代利什曼病与多发性骨髓瘤的共存：两例特殊病例的共同故事
Leuk Lymphoma. 2018 Apr;59(4):983-987. doi: 10.1080/10428194.2017.1361031. Epub 2017 Aug 7.
4
Leishmaniasis involving the bone marrow of a patient with multiple myeloma.
Ann Hematol. 2015 Aug;94(8):1417-8. doi: 10.1007/s00277-015-2376-1. Epub 2015 Apr 17.
5
An update on pharmacotherapy for leishmaniasis.利什曼病药物治疗的最新进展。
Expert Opin Pharmacother. 2015 Feb;16(2):237-52. doi: 10.1517/14656566.2015.973850. Epub 2014 Oct 25.
6
Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients.多发性骨髓瘤与感染：一项基于9253例多发性骨髓瘤患者的人群研究。
Haematologica. 2015 Jan;100(1):107-13. doi: 10.3324/haematol.2014.107714. Epub 2014 Oct 24.
7
Visceral leishmaniasis in a patient with relapsed multiple myeloma receiving high-dose melphalan and autologous stem cell transplant.一名复发多发性骨髓瘤患者在接受大剂量美法仑和自体干细胞移植时发生内脏利什曼病。
Leuk Lymphoma. 2014 Dec;55(12):2967-9. doi: 10.3109/10428194.2014.911862. Epub 2014 Jun 16.
8
Leishmaniasis in immunosuppressed individuals.免疫抑制个体中的利什曼病。
Clin Microbiol Infect. 2014 Apr;20(4):286-99. doi: 10.1111/1469-0691.12556. Epub 2014 Feb 20.
9
Mechanisms of immune evasion in leishmaniasis.利什曼病中的免疫逃逸机制。
Adv Appl Microbiol. 2013;82:155-84. doi: 10.1016/B978-0-12-407679-2.00005-3.
10
Visceral leishmaniasis: host-parasite interactions and clinical presentation in the immunocompetent and in the immunocompromised host.内脏利什曼病：免疫功能正常和免疫功能低下宿主中的寄生虫与宿主相互作用和临床表现。
Int J Infect Dis. 2013 Aug;17(8):e572-6. doi: 10.1016/j.ijid.2012.12.024. Epub 2013 Feb 4.